“Please don’t tell my family.” The stigma of lung cancer lives on. (ASCO Connection)
Radiologists were able to identify and report “critical issues” on chest x-rays more than a week earlier when they had help from an artificial intelligence system. (Radiological Society of North America)
England’s cost-effectiveness agency issued a favorable recommendation for the combination of venetoclax (Venclexta) and rituximab for adults with chronic lymphocytic leukemia.
Sometimes cancer is a laughing matter. (Journal of Clinical Oncology)
After almost 20 years of follow-up, a landmark clinical trial continued to show that finasteride “is safe, inexpensive, and effective” for preventing prostate cancer. (SWOG, New England Journal of Medicine)
Yet another study documenting hardships encountered by cancer patients. (Cancer)
The first-ever “digital pill” for oncology may help improve outcomes and adherence to treatment. (GlobalData)
AbbVie announced that its blockbuster leukemia drug ibrutinib (Imbruvica), in combination with chemotherapy, did not improve survival in metastatic pancreatic cancer, as compared with chemotherapy alone.
An early-detection test for esophageal cancer may have the potential to save “millions” of lives worldwide. (Johns Hopkins, Clinical Cancer Research)
Bristol-Myers Squibb withdrew its application for FDA approval of the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as first-line treatment for advanced lung cancer.
Former American Cancer Society (ACS) chief medical/scientific officer Otis Brawley, MD, joined the Johns Hopkins Bloomberg School of Public Health as head of a research program on cancer health disparities.
In follow-up to a recent announcement on olaratumab (Lartruvo), the European Medicines Agency recommended that no new sarcoma patients begin treatment with the agent. (European Society for Medical Oncology)
The second edition of the ACS National Cancer Control Blueprint addresses the current status of cancer control in the U.S.
Source: MedicalNewsToday.com
